[Edaily Starin Gim Ga Yeong Reporter] Actor Lee Jong-suk has decided not to appear in "Lee Seop’s Romance." Lee Jong-suk
On the 3rd, Ace Factory, Lee Jong-suk’s agency, stated, “Lee Jong-suk had been preparing to star in ‘Lee Seop’s Love’ after discussing the project in depth for a long time, starting from the planning and development stage. However, as the production and filming schedules were adjusted from the original plan, it became difficult to coordinate with his upcoming schedule.” They added, “After thorough discussions with the production team, we have reached a final agreement that he will not be participating in this project.” They continued, “As this is a project we have prepared for with great affection over a long period, we will do our best to ensure that ‘Lee Seop’s Romance’ is completed as a high-quality production.” Ace Factory, the production company behind *Lee Seop’s Romance*, explained, “We plan to recast the role of Lee Seop.” “Lee Seop’s Romance” is based on the web novel of the same name by author Kim Eun-hee. It is an office romance between Tae Lee-seop, who doesn’t want to do anything, and Kang Min-kyung, who must get things done no matter what. The story follows the romance between Tae Lee-seop—a third-generation chaebol heir who is perfect at everything except romance—and Kang Min-kyung, the “secret weapon” of TK Group. The series shares the same universe as writer Kim Eun-hee’s other web novel, *A Calm Lie*. Actor Lee Jun-hyuk stars as the lead in *A Calm Lie*. News of the production of both series was previously announced simultaneously, raising anticipation.
Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
On the 15th, the domestic pharmaceutical and biotech sector could not escape “Black Thursday.” Most stocks were unable to avoid declines. In the pharmaceutical sector, only 12 out of 161 stocks posted…
South Korea’s pharmaceutical and biotechnology sectors took a heavy hit on October 15, with the vast majority of stocks ending the session in negative territory. Of the 161 stocks in the pharmaceutica…